Helen of Troy Limited (NASDAQ:HELE) is a company known for its consumer healthcare and home products, including brands like OXO and PUR. On July 11, 2025, Peter Grom from UBS set a price target of $29 for HELE, suggesting a potential increase of about 27% from its then trading price of $22.84. However, recent financial results have raised concerns among investors.
The company's first-quarter fiscal 2026 results were disappointing, leading to a sharp 22.7% drop in its share price during after-hours trading. Earnings per share fell by 58.6% to $0.41, missing estimates due to lower income and higher interest expenses. Sales also decreased by 10.8% to $371.7 million, impacted by weak demand and tariff-related issues.
The gross margin declined by 160 basis points to 47.1%, pressured by trade-down, higher costs, and mix shifts. The underperformance was primarily due to significant tariff-related disruptions, including the cancellation of direct import orders from China and elevated inventory levels. These challenges have led to a Sell rating for the company, with a fair value estimated at $19 per share.
Helen of Troy faces major challenges, including tariff uncertainty, weak consumer demand, and a heavy reliance on large retailers, which limits its pricing power. The company is also burdened with a highly leveraged balance sheet, declining margins, and poor cash flow generation, increasing downside risk for shareholders. Despite these challenges, the stock is currently priced at $22.54, with a market capitalization of approximately $517.4 million.
